Synergistic anticancer effects of ganciclovir/thymidine kinase and 5- fluorocytosine/cytosine deaminase gene therapies

Journal of the National Cancer Institute

Volumn 90, Issue 5, 1998, Pages 370-380

  Aghi, Manish ^a   Kramm, Christof M ^a   Chou, Ting Chao ^b   Breakefield, Xandra O ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BACTERIAL ENZYME; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; NUCLEOSIDE ANALOG; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; VIRUS ENZYME;

ANIMAL CELL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL SURVIVAL; DNA SYNTHESIS INHIBITION; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; GENE THERAPY; HERPES SIMPLEX VIRUS; NONHUMAN; PHOSPHORYLATION; RNA SYNTHESIS;

EID: 0032481577     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.5.370     Document Type: Article

References (40)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
2. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, et al. Gene therapy for brain tumors. Brain Pathol 1995;5:345-81.
3. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995;2:702-9.
4. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
5. Mullen CA, Kilstrup M, Blase RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992;89:33-7.
6. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638.
7. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Longo DL. editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott. 1996:149-212.
8. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991;3: 608-14.
9. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-26.
10. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneim-Forsch 1953;3:285-320.
11. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
12. Chou TC. The median-effect principle and the combination index for quantification of synergism and antagonism. In: Chou, TC, Rideout, DC. editors. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:61-89.
13. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18: 3587-96.
14. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M. The 9L rat brain tumor: description and application of an animal model. J Neurol 1981;224:183-92.
15. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 1993;90:8392-6.
16. 50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. Manual and software for IBM-PC. Cambridge, England: Biosoft, 1987.
17. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976;59:253-76.
18. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL. Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type-1 thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992;33:493-503.
19. Koyano S, Suzutani T, Yoshida I, Azuma M. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Antimicrob Agents Chemother 1996;40:920-3.
20. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91:8302-6.
21. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53: 5274-83.
22. Rideout DC, Chou TC. Synergism, antagonism, and potentiation in chemotherapy: an overview. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:3-60.
23. Mini E, Bertino JR. Biochemical modulation of 5-fluorouracil by metabolites and antimetabolites. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:449-506.
24. Ikegami S, Taguchi T, Ohashi M, Oguno M, Nagano H, Mano Y. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-α. Nature 1978;275:458-60.
25. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
26. Sacks PG, Harris D, Chou TC. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer 1995;61:409-15.
27. Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996;37:222-8.
28. Prichard MN, Prichard LE, Shipman C Jr. Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir. Antivir Res 1993;20:249-59.
29. Harmenberg J. Intracellular pools of thymidine reduce the antiviral action of acyclovir. Intervirology 1983;20:48-51.
30. Chen MS, Walker J, Prusoff WH. Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme. J Biol Chem 1979;254:10747-53.
31. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48:455-84.
32. Tattersall MH, Harrap KR. Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil. Cancer Res 1973;33:3086-90.
33. Ives DH, Morse PA, Potter VR. Feedback inhibition of thymidine kinase by thymidine triphosphate. J Biol Chem 1963;238:1467-74.
34. Klemperer HG, Haynes GR, Shedden WI, Watson DH. A virus-specific thymidine kinase on BHK-21 cells infected with herpes simplex virus. Virology 1967;31:120-8.
35. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996;93:3525-9.
36. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995;31A:2362-70.
37. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997;8:1825-35.
38. Ram Z, Culver K, Oshiro E, Viola J, Devroom H, Otto E, et al. Summary of results and conclusions of the gene therapy of malignant brain tumors: a clinical study. J Neurosurg 1995;82:343A.
39. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Person DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.
40. RogulskiR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997;8:73-85.